Outcomes of sequential third-line therapies in patients with refractory overactive bladder.
botulinum toxin
incontinence
overactive bladder
sacral neuromodulation
urgency
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
received:
14
12
2023
accepted:
01
04
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
Sacral neuromodulation (SNM) and onabotulinumtoxinA (BoNTA) injection are third-line therapies for overactive bladder (OAB). Although the efficacy of each third-line treatment has been well established in clinical trials, there is far less information about performing one third-line therapy after the other. Our aim is thus to investigate the outcomes of post-SNM BoNTA and post-BoNTA SNM as "second" third-line treatments. We retrospectively reviewed all OAB patients who had both SNM and BoNTA between 2013 and 2022. The primary endpoint was the response rates (>50% improvements) of the second third-line treatments. Secondary endpoints were the proportion of the patients who achieved total dry, the duration of treatments of patients who had significant responses, and risk factors that are associated with treatment response or duration of treatments. A total of 172 patients had two third-line therapies. There were 104 patients who had post-SNM BoNTA and 68 patients who had post-BoNTA SNM. In the post-SNM BoNTA group, 62.5% (65/104) had significant responses after BoNTA treatment. In the post-BoNTA SNM group, 61.8% (44/68) had significant responses after SNM treatment. The proportions of patients who became dry were 21.2% and 23.5%, respectively. In the post-SNM BoNTA group, spinal pathology is associated with a lower probability of a significant response (48.9% vs. 73.7%, p-value = 0.0105). BoNTA or SNM remains a viable option for refractory OAB after patients fail from one another. Spinal pathology is associated with a poorer response of post-SNM BoNTA.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.
Références
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub‐committee of the international continence society. Neurourol Urodyn. 2002;21:167–178.
Chow PM, Kuo HC. Performance of urinary biomarkers in differentiating dysfunctional voiding in women with overactive bladder syndrome: a prospective pilot study. Int Urol Nephrol. 2022;54:2497–2502.
Ginsberg DA, Boone TB, Cameron AP, Gousse A, Kaufman MR, Keays E, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow‐up. J Urol. 2021;206:1106–1113.
Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects. Expert Rev Med Devices. 2022;19:161–187.
Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long‐term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency‐frequency, and retention. Urology. 2000;56:87–91.
Coolen RL, Groen J, Stillebroer AB, Scheepe JR, Witte LPW, Blok BFM. Two‐staged sacral Neuromodulation for the treatment of nonobstructive urinary retention: a multicenter study assessing predictors of success. Neuromodulation. 2022;25:S349–S350.
Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin a. Nat Rev Urol. 2015;12:519–533.
Yuan H, Cui Y, Wu J, Peng P, Sun X, Gao Z. Efficacy and adverse events associated with use of onabotulinumtoxinA for treatment of neurogenic detrusor overactivity: a meta‐analysis. Int Neurourol J. 2017;21:53–61.
Peters KM, Killinger KA, Ibrahim IA, Villalba PS. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency‐frequency. Neurourol Urodyn. 2008;27:775–778.
Chartier‐Kastler EJ, Ruud Bosch JL, Perrigot M, Chancellor MB, Richard F, Denys P. Long‐term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol. 2000;164:1476–1480.
Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81:738–743.
Liechti MD, van der Lely S, Knüpfer SC, Abt D, Kiss B, Leitner L, et al. Sacral Neuromodulation for neurogenic lower urinary tract dysfunction. NEJM Evidence. 2022;1. doi: 10.1056/EVIDoa2200071
Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral nerve stimulation study group. J Urol. 1999;162:352–357.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama á Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–2034.
Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta‐analysis. Eur Urol. 2010;58:865–874.
van Ophoven A, Engelberg S, Lilley H, Sievert KD. Systematic literature review and meta‐analysis of sacral neuromodulation (SNM) in patients with neurogenic lower urinary tract dysfunction (nLUTD): over 20 years' experience and future directions. Adv Ther. 2021;38:1987–2006.
Yang G, Xu Y, Qu G, Zhang Y. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed onabotulinumtoxinA treatment: a systematic review and meta‐analysis. PLoS One. 2020;15:e0230355.
Patra PB, Patra S. Sex differences in the physiology and pharmacology of the lower urinary tract. Curr Urol. 2013;6:179–188.
Anger JT, Cameron AP, Madison R, Saigal C, Clemens JQ, Urologic Diseases in America Project. Predictors of implantable pulse generator placement after sacral neuromodulation: who does better? Neuromodulation. 2014;17:381–384; discussion 4.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double‐blind, placebo‐controlled trial. Eur Urol. 2011;60:742–750.
Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–2139.
Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double‐blind, placebo‐controlled trial. Eur Urol. 2013;64:249–256.
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–2193.
Rovner E, Kohan A, Chartier‐Kastler E, Junemann KP, Del Popolo G, Herschorn S, et al. Long‐term efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016;196:801–808.
Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long‐term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5‐year study. J Urol. 2016;196:791–800.
Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, et al. High prevalence of neutralizing antibodies after long‐term botulinum neurotoxin therapy. Neurology. 2019;92:e48–e54.
Baron M, Perrouin‐Verbe MA, Lacombe S, Paret F, Le Normand L, Cornu JN. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder. Neurourol Urodyn. 2020;39:1012–1019.
Chen SF, Jiang YH, Jhang JF, Kuo HC. Satisfaction with detrusor onabotulinumtoxinA injections and conversion to other bladder management in patients with chronic spinal cord injury. Toxins. 2022;14.
Chen YH, Kuo HC. Botulinum a toxin treatment of urethral sphincter pseudodyssynergia in patients with cerebrovascular accidents or intracranial lesions. Urol Int. 2004;73:156–161; discussion 61–2.
Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology. 2006;67:232–236.
Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014;83:22–27.
Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, et al. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease. Neurourol Urodyn. 2018;37:2669–2677.